ストックスクリーナーアプリを入手
32.59
15.35%
4.385
前日終値:
$28.21
開ける：
$29.6
24時間の取引高:
10.53M
Relative Volume:
1.91
時価総額：
$23.32B
収益：
$13.31M
当期純損益:
$-1.01B
株価収益率:
-27.89
EPS:
-1.1685
ネットキャッシュフロー:
$-766.86M
1週間 パフォーマンス:
+11.36%
1か月 パフォーマンス:
+11.90%
6か月 パフォーマンス:
+60.53%
1年 パフォーマンス:
+194.75%
1日の値動き範囲:
$29.35
$32.79
1週間の範囲:
$27.85
$32.79
52週間の値動き範囲:
$10.59
$32.79
Roivant Sciences Ltd Stock (ROIV) Company Profile
Compare ROIV vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
32.59 | 20.43B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
428.83 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
643.20 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.26 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.38 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
150.90 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-20 | 開始されました | Bernstein | Outperform |
| 2025-09-02 | 開始されました | Citigroup | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-01-05 | 開始されました | Piper Sandler | Overweight |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-17 | 開始されました | Guggenheim | Buy |
| 2023-06-08 | 開始されました | BofA Securities | Neutral |
| 2022-10-27 | 開始されました | JP Morgan | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 開始されました | Goldman | Buy |
| 2021-11-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-28 | 開始されました | Citigroup | Buy |
| 2021-10-26 | 開始されました | Cowen | Outperform |
| 2021-10-26 | 開始されました | Jefferies | Buy |
| 2021-10-26 | 開始されました | Truist | Buy |
すべてを表示
Roivant Sciences Ltd (ROIV) 最新ニュース
ROIV: High efficacy in refractory RA, strong cash, and major launches expected in the coming year - TradingView
Roivant Sciences (ROIV) Surges 14.8% to $32.38 - AlphaStreet
Roivant Sciences Shares Jump 14.43% to $32.28 on Strong IMVT-1402 Rheumatoid Arthritis Data - International Business Times Australia
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2026 - marketscreener.com
Roivant gains after mid-stage trial data for Immunovant’s main asset - Seeking Alpha
Roivant Sciences Q4 Earnings Call Highlights - Yahoo Finance
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Movin - Benzinga
Roivant Sciences stock hits all-time high of 30.35 USD - Investing.com
Roivant Sciences Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Roivant Sciences surprises with Q4 2026 EPS beat - Investing.com
Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV) - Yahoo Finance
Roivant Sciences : Financial Results and Business Updates for the Year Ended March 31 2026 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
ROIV: Strong clinical progress, major litigation win, and robust cash position set up multiple 2027 catalysts - TradingView
Roivant Sciences Ltd. Reports FY2025 Financial Results and Key Developments in May 2026 - Minichart
Roivant shares jump 10% on earnings beat despite revenue miss By Investing.com - Investing.com Australia
Roivant Sciences Ltd. 2026 Annual Report: Business Overview, Risk Factors, and Product Pipeline Highlights - Minichart
Roivant shares jump 10% on earnings beat despite revenue miss - Investing.com
Roivant Sciences Ltd. FY 2026: Revenue $8.26M, EPS ($0.54) — 10-K Summary - TradingView
Roivant Reports $355.7M Q4 Income from Continuing Ops, $4.3B Cash Position - TradingView
Earnings Flash (ROIV) Roivant Posts Fiscal Q4 EPS From Continuing Operations $0.28 - marketscreener.com
Roivant (ROIV) touts late-stage pipeline and Genevant’s $2.25B Moderna IP deal - Stock Titan
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q4 Revenue $2.5M, vs. FactSet Est of $3.4M - marketscreener.com
Roivant (NASDAQ: ROIV) books $770M legal gain and holds $4.3B cash - Stock Titan
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update - The Manila Times
Roivant Sciences Ltd. (ROIV) Tops Q4 EPS by 57c - StreetInsider
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside - TradingView
Roivant Sciences Q4 2026 earnings preview - MSN
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why - sharewise.com
A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus - simplywall.st
Roivant in the spotlight as earnings loom with approval ahead - Investing.com India
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight - GlobeNewswire Inc.
Book value per share of Roivant Sciences Ltd. – LSX:A3C4MS - TradingView
Roivant Sciences Q4 2026 Earnings Preview — May 20, Street Expects -$0.35 EPS - AlphaStreet
Trading the Move, Not the Narrative: (ROIV) Edition - Stock Traders Daily
Earnings Preview: ROIV to Report Financial Results Pre-market on May 20 - Moomoo
ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings - ChartMill
TradingKey - TradingKey
ROIV Q4'25 Earnings: revenue estimate is 3.41M USD - TradingView
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a 24.88% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
ROIV Stock Price, Quote & Chart | ROIVANT SCIENCES LTD (NASDAQ:ROIV) - ChartMill
Insiders At Roivant Sciences Sold US$112m In Stock, Alluding To Potential Weakness - Moomoo
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
A Look At Roivant Sciences (ROIV) Valuation After Encouraging Phase 2 Brepocitinib Data - Yahoo Finance
Baron Fund Puts Spotlight On Roivant’s Brepocitinib And Valuation Gap - simplywall.st
Assessing Roivant Sciences (ROIV) Valuation After Strong 1-Year Return And Recent Share Price Momentum - simplywall.st
Who is Vivek Ramaswamy, 2026 Republican nominee for Ohio governor? - marketscreener.com
MSN Money - MSN
Baron Health Care Fund Reports Roivant Sciences as Top Q1 2026 Performer - HarianBasis.co
Roivant Sciences Ltd (ROIV) 財務データ
収益
当期純利益
現金流量
EPS
Roivant Sciences Ltd (ROIV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Apr 20 '26 |
Sale |
29.59 |
200,000 |
5,918,000 |
1,647,546 |
| Gline Matthew | CEO |
Apr 16 '26 |
Sale |
29.16 |
289,774 |
8,449,810 |
16,736,116 |
0.67%
大文字化:
|
ボリューム (24 時間):